Screener
Insight Molecular Diagnostics Inc. IMDX Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $17.76M-26.9% | $28.2M-9.1% | $11.58M+34.1% | $18.69M+456% | $24.29M+162% | ||
| $192K-62.5% | $157K-95.6% | $1.13M-30.1% | $258K+23.4% | $512K+502% | ||
| $207K-70.1% | $382K-16.8% | $446K+8.8% | $471K+103% | $693K— | ||
| $20.54M-23.5% | $30.52M-15.8% | $15.31M+30.2% | $21.39M+346% | $26.84M+169% | ||
| $29.44M-41.7% | $40.43M-33.0% | $25.76M-26.6% | $43.94M-37.4% | $50.52M-32.4% | ||
| $1.87M+46.5% | $1.62M-29.1% | $2.54M+55.0% | $1.06M+21.1% | $1.28M+21.5% | ||
| $10.29M+54.6% | $12.01M+24.0% | $12.08M+66.0% | $7.66M-15.7% | $6.65M-7.6% | ||
| $50.74M+2.7% | $51.12M+1.9% | $57.22M+20.8% | $53.13M-12.2% | $49.42M-5.0% | ||
| $394.95M+7.3% | $394.29M+7.3% | $369.21M+9.2% | $368.52M+60.2% | $367.97M+60.0% | ||
| -$416.31M-13.5% | -$405.05M-13.4% | -$400.76M-14.3% | -$377.81M-19.2% | -$366.95M-20.9% | ||
| -$21.3M-2,040% | -$10.69M-205% | -$31.46M-156% | -$9.2M-195% | $1.1M-95.2% | ||
| $29.44M-41.7% | $40.43M-33.0% | $25.76M-26.6% | $43.94M-37.4% | $50.52M-32.4% |
FAQ
- What are Insight Molecular Diagnostics Inc.'s total assets?
- Insight Molecular Diagnostics Inc. (IMDX) holds $29.4M in total assets, down 41.7% year over year.
- How much debt does Insight Molecular Diagnostics Inc. have?
- Insight Molecular Diagnostics Inc. carries $2.4M in total debt against -$21.3M of shareholders' equity, a debt-to-equity ratio of 2.91.
- How much cash does Insight Molecular Diagnostics Inc. have?
- Insight Molecular Diagnostics Inc. holds $17.8M in cash and equivalents.
- Can Insight Molecular Diagnostics Inc. cover its short-term obligations?
- Its current ratio is 2.00 — current assets exceed current liabilities.
- Where does Insight Molecular Diagnostics Inc.'s balance sheet data come from?
- Every line is extracted from Insight Molecular Diagnostics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
